Profile data is unavailable for this security.
About the company
Camurus AB is a Sweden-based research and development based pharmaceutical and biotechnology company with a focus on the development and marketing of specialty medicines, providing patients suffering from severe and chronic disease, such as opioid dependence, pain, cancer, and endocrine diseases. The Company has a diversified research portfolio, which includes products in clinical trials. The Company’s products are based on FluidCrystal formulation technology. FluidCrystal is Company's patent-protected technology platform. Camurus AB is the parent company of the Group, which comprises of legal entities, namely: Camurus Inc, Cubosome Inc, Development AB, Camurus GmbH, Camurus Ltd, Camurus Oy, Camurus AS, Camurus SAS, Camurus Pty Ltd, Camurus S.L, Camurus ApS, Camurus BV and Camurus Austria GmbH.
- Revenue in SEK (TTM)1.82bn
- Net income in SEK450.48m
- Incorporated2004
- Employees218.00
- LocationCamurus ABIdeongatan 1ALUND 223 62SwedenSWE
- Phone+46 462865730
- Fax+46 462865739
- Websitehttps://www.camurus.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Swedencare AB (publ) | 2.41bn | 71.50m | 8.97bn | 552.00 | 125.43 | 1.16 | 23.39 | 3.72 | 0.4505 | 0.4505 | 15.21 | 48.80 | 0.2412 | 2.35 | 9.52 | 4,966,461.00 | 0.7144 | 1.38 | 0.7361 | 1.43 | 55.64 | 55.34 | 2.96 | 5.10 | 1.82 | 2.21 | 0.1746 | 45.33 | 27.48 | 88.16 | -37.96 | 20.24 | 30.90 | -- |
| BioGaia AB | 1.30bn | 371.25m | 11.99bn | 211.00 | 33.54 | 5.74 | 30.31 | 9.22 | 3.68 | 3.68 | 12.88 | 21.47 | 0.5414 | -- | -- | 6,192,767.00 | 15.46 | 15.47 | 16.82 | 16.93 | 73.32 | 73.30 | 28.55 | 27.70 | -- | -- | 0.00 | 104.42 | 17.44 | 11.81 | -2.25 | 11.20 | 29.27 | 28.10 |
| Calliditas Therapeutics AB | 1.31bn | -524.82m | 12.25bn | 219.00 | -- | 91.84 | -- | 9.34 | -9.78 | -9.78 | 24.43 | 2.24 | 0.7541 | 3.16 | 8.97 | 6,723,169.00 | -30.19 | -26.46 | -38.05 | -30.27 | 95.01 | -- | -40.03 | -76.59 | 2.62 | -3.99 | 0.8943 | -- | 50.32 | -- | -13.08 | -- | -- | -- |
| Vimian Group AB | 3.79bn | 89.73m | 17.21bn | 1.10k | 172.66 | 2.57 | 36.40 | 4.54 | 0.1928 | 0.1928 | 8.09 | 12.97 | 0.3354 | 2.83 | 5.69 | 3,442,408.00 | 0.867 | -- | 1.01 | -- | 47.48 | -- | 2.59 | -- | 1.19 | 2.81 | 0.3729 | -- | 17.92 | -- | 245.95 | -- | -- | -- |
| Bonesupport Holding AB | 655.75m | 266.56m | 17.30bn | 121.00 | 65.07 | 30.56 | 62.43 | 26.38 | 4.05 | 4.05 | 9.96 | 8.61 | 1.19 | 0.657 | 6.36 | 6,245,276.00 | 48.22 | -9.08 | 61.41 | -11.28 | 92.01 | 90.25 | 40.65 | -11.65 | 2.42 | -- | 0.0282 | -- | 79.76 | 43.65 | 459.44 | -- | 18.39 | -- |
| Bavarian Nordic A/S | 10.08bn | 1.49bn | 20.74bn | 1.38k | 13.61 | 1.34 | 8.67 | 2.06 | 12.86 | 12.86 | 86.59 | 130.35 | 0.4956 | 1.74 | 9.32 | 4,816,359.00 | 7.35 | 1.21 | 8.92 | 1.48 | 60.90 | 53.72 | 14.82 | 4.06 | 1.03 | -- | 0.0427 | 0.00 | 124.14 | 69.78 | 524.66 | -- | 35.76 | -- |
| Camurus AB | 1.82bn | 450.48m | 34.36bn | 218.00 | 75.23 | 12.76 | 73.91 | 18.85 | 7.79 | 7.79 | 31.75 | 45.91 | 0.8265 | 1.14 | 6.65 | 8,557,742.00 | 20.43 | -1.13 | 23.79 | -1.41 | 93.17 | 90.05 | 24.71 | -1.63 | 7.39 | -- | 0.0086 | -- | 79.52 | 103.39 | 676.63 | -- | 16.29 | -- |
| ALK-Abello A/S | 7.50bn | 842.25m | 47.13bn | 2.83k | 61.51 | 7.23 | 36.45 | 6.28 | 2.49 | 2.49 | 21.93 | 21.19 | 0.752 | 1.29 | 5.81 | 1,749,646.00 | 8.45 | 3.50 | 10.36 | 4.37 | 63.25 | 60.66 | 11.23 | 5.07 | 1.23 | 50.27 | 0.0995 | 0.00 | 6.94 | 10.60 | 45.07 | -- | 16.32 | -- |
| Orion Oyj | 13.81bn | 2.45bn | 66.12bn | 3.70k | 26.83 | 8.24 | 22.12 | 4.79 | 1.55 | 1.55 | 8.71 | 5.04 | 0.8866 | 1.57 | 6.01 | 336,013.20 | 15.73 | 19.47 | 21.38 | 24.16 | 55.10 | 59.38 | 17.74 | 20.71 | 1.00 | 74.43 | 0.2157 | 91.83 | -11.26 | 4.01 | -37.97 | 1.89 | 11.82 | 1.55 |
| Swedish Orphan Biovitrum AB (publ) | 23.14bn | 2.14bn | 96.60bn | 1.75k | 44.04 | 2.58 | 17.39 | 4.17 | 6.19 | 6.19 | 69.32 | 105.59 | 0.3603 | 1.50 | 4.72 | 13,058,130.00 | 3.33 | 5.93 | 4.43 | 7.60 | 76.60 | 77.42 | 9.25 | 16.61 | 0.4994 | 3.56 | 0.3487 | 0.00 | 17.74 | 19.34 | -8.68 | -0.0729 | 53.61 | -- |
Data as of Jul 04 2024. Currency figures normalised to Camurus AB's reporting currency: Swedish Krona SEK
17.83%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fj�rde AP-fondenas of 31 May 2024 | 2.61m | 4.53% |
| Swedbank Robur Fonder ABas of 31 May 2024 | 1.85m | 3.20% |
| Handelsbanken Fonder ABas of 31 May 2024 | 1.41m | 2.45% |
| The Vanguard Group, Inc.as of 06 Jun 2024 | 1.15m | 2.00% |
| Lancelot Asset Management ABas of 31 Dec 2022 | 625.00k | 1.09% |
| AFA Sjukf�rs�kringsaktiebolag (Invt Mgmt)as of 31 May 2024 | 614.29k | 1.07% |
| SEB Investment Management ABas of 31 May 2024 | 613.56k | 1.07% |
| Devon Equity Management Ltd.as of 31 May 2024 | 584.48k | 1.01% |
| Didner & Gerge Fonder ABas of 31 Dec 2023 | 428.50k | 0.74% |
| Baillie Gifford & Co.as of 31 May 2024 | 391.21k | 0.68% |
More ▼
Data from 30 Jun 2023 - 03 Jun 2024Source: FactSet Research Systems Inc.
